PTH 1-84 (Full-Length Parathyroid Hormone)
PTH 1-84 is the full-length 84-amino acid parathyroid hormone, the primary endogenous regulator of calcium homeostasis. Available as Natpara (for hypoparathyroidism) and previously Preotact (for osteoporosis in Europe), it shares the anabolic bone-forming properties of its N-terminal fragment teriparatide (PTH 1-34) while including a C-terminal domain with potentially distinct biological effects.
PTH 1-84 is the intact, full-length 84-amino acid parathyroid hormone — the endogenous master regulator of calcium and phosphorus metabolism. It is secreted by the parathyroid glands in response to low ionized calcium and acts on bone and kidney to restore calcium homeostasis.
Overview
Parathyroid hormone is secreted as the 84-amino acid mature peptide after processing from pre-pro-PTH (115 amino acids). The parathyroid glands contain a calcium-sensing receptor (CaSR) that detects circulating ionized calcium and inversely regulates PTH secretion — low calcium triggers PTH release; high calcium suppresses it. This minute-to-minute feedback loop maintains serum calcium within a remarkably narrow range (8.5-10.5 mg/dL).
The full-length hormone has been less commercially successful than its 1-34 fragment for osteoporosis (Preotact was withdrawn from the European market in 2014 for commercial reasons, not safety), but has found an important niche in hypoparathyroidism — a condition where replacement of the missing hormone is the logical therapeutic approach. Natpara was the first PTH replacement therapy approved for hypoparathyroidism, though it has faced supply challenges and a voluntary recall related to rubber particulates in cartridges.
Mechanism of Action
N-Terminal Signaling (Residues 1-34)
The first 34 residues of PTH are necessary and sufficient for full activation of the PTH type 1 receptor (PTH1R). This region drives all classical PTH actions:
- Gs/cAMP/PKA activation: Stimulates adenylyl cyclase, increasing cAMP and activating PKA-dependent gene transcription in osteoblasts and renal tubular cells.
- Gq/PLC/PKC activation: Increases intracellular calcium and PKC activity.
- Wnt pathway modulation: Suppresses sclerostin (SOST) production by osteocytes, activating Wnt/beta-catenin signaling for osteoblast differentiation (Keller & Kneissel, 2005).
- RANKL/OPG regulation: Intermittent exposure favors OPG (anti-resorptive); continuous exposure shifts toward RANKL (pro-resorptive).
Because both PTH 1-84 and PTH 1-34 contain this N-terminal domain, their PTH1R-mediated effects are qualitatively identical. The difference lies in the C-terminal region.
C-Terminal PTH Biology
The C-terminal fragment of PTH (broadly, residues 35-84) has been a subject of evolving research. Key findings:
- C-terminal PTH receptors (CPTHRs): Distinct from PTH1R, these putative receptors bind C-terminal PTH fragments and appear to mediate effects that oppose or modulate N-terminal signaling. They have been identified on osteoblasts and osteocytes, though molecular cloning of the receptor remains incomplete (Divieti et al., 2005).
- PTH 7-84 as an endogenous antagonist: The large C-terminal fragment PTH 7-84 accumulates in renal failure and appears to antagonize some effects of intact PTH, particularly the calcemic response. This may explain why patients with chronic kidney disease can have high intact PTH yet develop adynamic bone disease (Nguyen-Yamamoto et al., 2010).
- Anti-resorptive C-terminal effects: Some evidence suggests C-terminal PTH fragments inhibit osteoclast activity, potentially attenuating the resorptive component of full-length PTH's skeletal effects. This could theoretically produce a more favorable formation/resorption balance with PTH 1-84 compared to PTH 1-34.
- Phosphaturic effects: C-terminal PTH fragments may have independent effects on renal phosphate handling.
Calcium Homeostasis
Full-length PTH is the physiological regulator of calcium balance:
- Bone: Mobilizes calcium from bone through osteoclast activation (continuous exposure) or stimulates bone formation (intermittent exposure).
- Kidney: Increases calcium reabsorption in the distal tubule; decreases phosphate reabsorption in the proximal tubule; stimulates 1-alpha-hydroxylase to convert 25(OH)D to active 1,25(OH)2D (calcitriol).
- Intestine: Indirectly increases calcium absorption through calcitriol production.
Research
Osteoporosis (TOP Study)
The Treatment of Osteoporosis with Parathyroid Hormone (TOP) study randomized 2,532 postmenopausal women to PTH 1-84 (100 mcg/day) or placebo for 18 months. PTH 1-84 reduced new vertebral fractures by 58% and increased lumbar spine BMD by 6.9%. However, non-vertebral fracture reduction did not reach statistical significance (Greenspan et al., 2007).
Comparison with Teriparatide
Direct comparisons between PTH 1-84 and PTH 1-34 have shown generally similar efficacy for bone formation:
- Both agents increase spine BMD by comparable magnitudes (PTH 1-84: ~7% at 18 months; PTH 1-34: ~9-10% at 18 months at the approved dose).
- PTH 1-84 produces more sustained hypercalcemia due to its longer half-life, which may limit dose escalation.
- The theoretical advantage of C-terminal-mediated anti-resorptive effects has not translated into clearly superior clinical outcomes in trials.
- PTH 1-34 has a more extensive clinical evidence base and remains the dominant PTH-based osteoporosis therapy globally (Hodsman et al., 2005).
Hypoparathyroidism (REPLACE Study)
The REPLACE trial established the efficacy of PTH 1-84 for hypoparathyroidism. In this 24-week randomized trial, PTH 1-84 (50-100 mcg/day) enabled a significant proportion of patients to reduce or eliminate calcium and calcitriol supplementation while maintaining serum calcium in the target range. 53% of PTH 1-84-treated patients achieved the composite endpoint versus 2% with placebo (Mannstadt et al., 2013).
This is a physiologically rational approach — replacing the missing hormone rather than managing the downstream consequences with calcium and vitamin D supplements. Benefits include:
- Reduced exogenous calcium and calcitriol requirements
- More stable serum calcium levels
- Reduced urinary calcium excretion (lowering nephrolithiasis risk)
- Potential improvements in quality of life and neurocognitive symptoms
Abaloparatide Comparison
Abaloparatide, a synthetic analog of PTHrP(1-34), acts on the same PTH1R receptor but with selectivity for the RG (signaling-competent) conformation. Compared to PTH-based agents:
- Abaloparatide produces faster BMD gains at some sites with lower hypercalcemia incidence than teriparatide.
- Neither PTH 1-84 nor PTH 1-34 has been directly compared with abaloparatide in a head-to-head trial, though the ACTIVE trial compared abaloparatide with teriparatide and placebo.
PTHrP Biology
Parathyroid hormone-related protein (PTHrP) shares N-terminal homology with PTH (8 of the first 13 residues are identical) and activates the same PTH1R receptor. However, PTHrP is primarily a paracrine factor involved in:
- Endochondral bone development
- Breast and smooth muscle physiology
- Tooth eruption
- Humoral hypercalcemia of malignancy (when produced ectopically by tumors)
The distinct signaling kinetics of PTHrP versus PTH at PTH1R (PTHrP produces more transient cAMP responses) provided the rationale for developing abaloparatide as a potentially superior bone anabolic agent.
Safety Profile
PTH 1-84 shares the general safety profile of PTH-based therapies:
- Hypercalcemia: More frequent and sustained than with teriparatide due to the longer half-life. Requires serum calcium monitoring, particularly during dose titration.
- Nausea: Common (15-20%), generally mild and transient.
- Hypocalcemia risk: In hypoparathyroidism patients during dose adjustment, particularly if calcium/calcitriol supplementation is reduced too rapidly.
- Osteosarcoma warning: Same black box warning as teriparatide based on rat studies, though the human relevance is considered low.
- Natpara-specific: Voluntary recall (2019) due to potential rubber particulate matter in drug cartridges. Supply has been limited.
Pharmacokinetic Profile
PTH 1-84 (Full-Length Parathyroid Hormone) — Pharmacokinetic Curve
Subcutaneous injectionQuick Start
- Route
- Subcutaneous injection
Research Protocols
subcutaneous Injection
Administered via subcutaneous injection.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Remarkably narrow range | 8.5-10.5 mg | Per protocol | — |
| Osteoporosis with Parathyroid Hormone | 100 mcg | Per protocol | 18 months |
| This | 50-100 mcg | Per protocol | — |
Interactions
Peptide Interactions
Direct comparisons between PTH 1-84 and PTH 1-34 have shown generally similar efficacy for bone formation: - Both agents increase spine BMD by comparable magnitudes (PTH 1-84: ~7% at 18 months; PTH 1-34: ~9-10% at 18 months at the approved dose). - PTH 1-84 produces more sustained hypercalcemia d...
What to Expect
What to Expect
Effects begin within hours of administration based on half-life of ~2.5 hours (subcutaneous)
In this 24-week randomized trial, PTH 1-84 (50-100 mcg/day) enabled a significant proportion of patients to reduce or eliminate calcium and...
The Treatment of Osteoporosis with Parathyroid Hormone (TOP) study randomized 2,532 postmenopausal women to PTH 1-84 (100 mcg/day) or placebo for 18...
Continued use as directed
Quality Indicators
What to look for
- Multiple peer-reviewed studies available
Caution
- Commonly used off-label
Red flags
- Significant side effect risk noted
Frequently Asked Questions
References (7)
- [2]Mannstadt M et al Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE) J Clin Endocrinol Metab (2013)
- [1]
- [4]Nguyen-Yamamoto L et al Parathyroid hormone (PTH) 7-84 inhibits the effects of PTH on calcium homeostasis Endocrinology (2010)
- [3]Divieti P et al Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells J Biol Chem (2005)
- [5]Hodsman AB et al Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use Endocr Rev (2005)
- [6]
- [7]Rubin MR et al Long-term effects of recombinant human parathyroid hormone (1-84) on skeletal outcomes in hypoparathyroidism J Bone Miner Res (2016)
PTH 1-34 (Teriparatide / Forteo)
Teriparatide is a recombinant 34-amino acid N-terminal fragment of human parathyroid hormone (PTH). FDA-approved in 2002 for osteoporosis, it is the first anabolic bone agent, stimulating osteoblast-mediated bone formation through intermittent PTH1R receptor activation. It significantly increases bone mineral density and reduces fracture risk.
RANTES / CCL5-Derived Peptides
RANTES (Regulated upon Activation, Normal T cell Expressed and Secreted), officially designated CCL5, is a 68-amino acid CC chemokine that signals through CCR1, CCR3, and CCR5 receptors to orchestrate immune cell trafficking. CCL5/CCR5 signaling plays dual roles in the tumor microenvironment — promoting anti-tumor immunity through T cell recruitment while also facilitating tumor-promoting inflammation and metastasis. CCR5 is a major HIV-1 co-receptor, and CCL5-derived antagonists including Met-RANTES have informed the development of CCR5 inhibitors such as maraviroc. Cancer immunotherapy applications targeting the CCL5/CCR5 axis are under active investigation.